Divergent Rifamycin Susceptibilities of Clostridium Difficile Strains in Canada and Italy and Predictive Accuracy of Rifampin Etest for Rifamycin Resistance

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2011 Oct 15

PMID 21998414

Citations 14

Authors

Mark A Miller

Ruth Blanchette

Patrizia Spigaglia

Fabrizio Barbanti

Paola Mastrantonio

Affiliations

Soon will be listed here.

Abstract

We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180 Clostridium difficile clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, >16 μg/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new rpoB mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.

Citing Articles

Antibiotic Resistances of Clostridioides difficile.

Spigaglia P, Mastrantonio P, Barbanti F Adv Exp Med Biol. 2024; 1435:169-198.

PMID: 38175476 DOI: 10.1007/978-3-031-42108-2_9.

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.

DuPont H Clin Microbiol Rev. 2023; 36(4):e0003923.

PMID: 37971270 PMC: 10732030. DOI: 10.1128/cmr.00039-23.

Antimicrobial resistance in Clostridioides difficile.

OGrady K, Knight D, Riley T Eur J Clin Microbiol Infect Dis. 2021; 40(12):2459-2478.

PMID: 34427801 DOI: 10.1007/s10096-021-04311-5.

Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.

Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L Antimicrob Resist Infect Control. 2020; 9(1):158.

PMID: 32977835 PMC: 7517813. DOI: 10.1186/s13756-020-00815-5.

Conventional and alternative treatment approaches for infection.

Aljarallah K Int J Health Sci (Qassim). 2017; 11(1):1-10.

PMID: 28293151 PMC: 5327666.

References

Musher D, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40(11):1586-90. DOI: 10.1086/430311. View

Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M, Citron D . Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis. 2010; 50(12):e77-81. DOI: 10.1086/653012. View

. Treatment of clostridium difficile infection. Med Lett Drugs Ther. 2011; 53(1358):14-5. View

Scarpellini E, Gabrielli M, Lauritano C, Lupascu A, Merra G, Cammarota G . High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007; 25(7):781-6. DOI: 10.1111/j.1365-2036.2007.03259.x. View

Curry S, Marsh J, Shutt K, Muto C, OLeary M, Saul M . High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009; 48(4):425-9. PMC: 2819169. DOI: 10.1086/596315. View

Hecht D, Galang M, Sambol S, Osmolski J, Johnson S, Gerding D . In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007; 51(8):2716-9. PMC: 1932509. DOI: 10.1128/AAC.01623-06. View

OConnor J, Galang M, Sambol S, Hecht D, Vedantam G, Gerding D . Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(8):2813-7. PMC: 2493101. DOI: 10.1128/AAC.00342-08. View

Fawley W, Wilcox M . Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains. J Clin Microbiol. 2002; 40(9):3546-7; author reply 3547. PMC: 130783. DOI: 10.1128/JCM.40.9.3546-3547.2002. View

Baines S, OConnor R, Freeman J, Fawley W, Harmanus C, Mastrantonio P . Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother. 2008; 62(5):1046-52. DOI: 10.1093/jac/dkn313. View

10.

Murphy C, Mullin S, Osburne M, van Duzer J, Siedlecki J, Yu X . In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(3):827-34. PMC: 1426431. DOI: 10.1128/AAC.50.3.827-834.2006. View

11.

Cellai L, Colosimo M, Marchi E, Venturini A, Zanolo G . Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia. 1984; 3(6):373-7. View

12.

Louie T, Miller M, Donskey C, Mullane K, Goldstein E . Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2008; 53(1):223-8. PMC: 2612138. DOI: 10.1128/AAC.01442-07. View

13.

Campbell E, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A . Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 2001; 104(6):901-12. DOI: 10.1016/s0092-8674(01)00286-0. View

14.

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

15.

Louie T, Miller M, Mullane K, Weiss K, Lentnek A, Golan Y . Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5):422-31. DOI: 10.1056/NEJMoa0910812. View

16.

Scarpignato C, Pelosini I . Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005; 51 Suppl 1:36-66. DOI: 10.1159/000081990. View

17.

Jiang Z, DuPont H, La Rocco M, Garey K . In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010; 63(4):355-8. DOI: 10.1136/jcp.2009.071688. View

18.

Garey K, Salazar M, Shah D, Rodrigue R, DuPont H . Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008; 42(6):827-35. DOI: 10.1345/aph.1K675. View

19.

Pepin J, Alary M, Valiquette L, Raiche E, Ruel J, Fulop K . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40(11):1591-7. DOI: 10.1086/430315. View

20.

Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz J, Bouza E . Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002; 46(6):1647-50. PMC: 127235. DOI: 10.1128/AAC.46.6.1647-1650.2002. View